Is Cardiol Therapeutics Inc. (CRDL) a Buy, Sell, or Hold?
NASDAQ : CRDL
Cardiol Therapeutics Inc.
$1.21 USD
-$0.02 (-1.63%)
- Volume
- 1.41M
- Average Volume
- 535.73K
- Market Capitalization
- $139.48M
- P/E Ratio
- -4.32
- Dividend Yield
- 0.00%
- Price Target
- $8.00
- Year High
- $1.71
- Year Low
- $0.88
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.39
Company Overview
NASDAQ
David G. Elsley
Drug Manufacturers - Specialty & Generic
Healthcare
CRDL
18
CA
USD
Liquidity Metrics
0.00
4.39
4.39
3.88
0.00
Sales & Valuation
-$
0.00
7.61
-8.02
-0.22
Profitability
-$0.39
-$33.82M
0.00%
0.00%
-229.16%
-115.74%
P/E Metrics
-4.32
-0.21
-0.21
Analyst Price Target & Rating
$8.00
$8.00
$8.00
2/5
2 Analysts
-84.88%
Poll Results
About Cardiol Therapeutics Inc. (NASDAQ:CRDL) Stock
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was establ ... ished in 2017 and operates from its headquarters in Oakville, Canada.
2026-07-14 07:27:00
• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion. TORONTO, July 14, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association ("JAHA").
2026-07-09 07:27:00
TORONTO, July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston, MA, on July 16, 2026, at 12:20 p.m.
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
2026-06-25 07:27:00
TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on June 24, 2026. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated May 7, 2026.
2026-06-23 07:27:00
TORONTO, June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 24, 2026, at 4:30 p.m. EDT. Cardiol Therapeutics' 2026 AGM When: June 24, 2026, at 4:30 p.m.
2026-05-14 07:27:00
TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York, NY, on May 19, 2026, at 1:30 p.m.
2026-05-07 07:27:00
Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% enrollment. TORONTO, ON, May 7, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association ("JAHA").
2026-04-28 07:27:00
Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Langone Health, Lenox Hill Hospital/Northwell Health, and Houston Methodist Hospital. Growing interest in MAVERIC is expected to support the activation of up to seven additional U.S. clinical centers, with the total number anticipated to reach 25.
Contrasting Corcept Therapeutics (NASDAQ:CORT) & Cardiol Therapeutics (NASDAQ:CRDL)
2026-04-24 02:31:15
Corcept Therapeutics (NASDAQ: CORT - Get Free Report) and Cardiol Therapeutics (NASDAQ: CRDL - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends. Valuation and Earnings This table compares Corcept Therapeutics
Frequently Asked Questions
-
What is the current Cardiol Therapeutics Inc. (CRDL) stock price?
-
Cardiol Therapeutics Inc.(NASDAQ:CRDL) stock price is $1.21 in the last trading session. During the trading session, CRDL stock reached the peak price of $1.71 while $0.88 was the lowest point it dropped to. The percentage change in CRDL stock occurred in the recent session was --1.63% while the dollar amount for the price change in CRDL stock was -$0.02.
-
CRDL's industry and sector of operation?
-
The NASDAQ listed CRDL is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of CRDL?
-
Andrew Warwick Hamer | Chief Medical Officer and Head of Research & Development
Trevor Burns | Investor Relations
Bernard Lim | Chief Operating Officer
John A. Geddes BSCPT | Vice President of Corporate Development
Christopher J. Waddick | Chief Financial Officer, Corporate Secretary & Director -
How many employees does CRDL have?
-
Number of CRDL employees currently stands at 18. CRDL operates from 2265 Upper Middle Road East, Oakville, ON L6H 0G5, CA.
-
Link for CRDL official website?
-
Official Website of CRDL is: https://www.cardiolrx.com
-
How do I contact CRDL?
-
CRDL could be contacted at phone #289 910 0850 and can also be accessed through its website. CRDL operates from 2265 Upper Middle Road East, Oakville, ON L6H 0G5, CA.
-
How many shares of CRDL are traded daily?
-
The average number of CRDL shares traded daily for last 3 months was 535.73K.
-
What is the market cap of CRDL currently?
-
The market value of CRDL currently stands at $139.48M with its latest stock price at $1.21